

Plasma Proteins

Edited by

Birger Blombäck

*Department of Coagulation Research
Karolinska Institute, Stockholm*

Lars Å. Hanson

*Institute of Medical Microbiology,
University of Gothenburg*

Coordinating Editor

Håkan Winberg *KABI AB*

Translated from the Swedish by Dr Desmond Hogg

A Wiley-Interscience Publication

A KABI book

JOHN WILEY & SONS

Chichester · New York · Brisbane · Toronto

First published by AB Kabi in 1976 under the title *Plasmaproteiner*
edited by Birger Blombäck and Lars Å. Hanson

© B. Blombäck, L. Å. Hanson, L.-O. Andersson, H. Bennich, G. Birke, H. Björling, G. Cederblad, G. Claes, M. Einatsson, B. Gullbring, A. Gustafson, L. Holmberg, B. G. Johansson, S.-O. Liljedahl, R. Lundén S. Magnusson, G. Möller, H. Nihlén, K. O. Pedersen, J. A. G. Rhodin, M. Rothschild, P. Wallén
KABI AB

Copyright © 1979 by John Wiley & Sons, Ltd.
All rights reserved.

No part of this book may be reproduced by any means, nor transmitted,
nor translated into a machine language without the written
permission of the publisher.

Library of Congress Cataloging in Publication Data:

Main entry under title:

Plasma proteins.

Translation of *Plasmaproteiner*.

'A Wiley-Interscience publication.'

Includes index.

1. Plasma proteins. I. Blombäck, Birger.

II. Hanson, Lars A. [DNLM: 1. Blood proteins. WH400 P716]

QP99.3.P7P5713 612'.12 78-10126

ISBN 0 471 99730 7

Photoset in Malta by Interprint Limited
and printed in Great Britain by The Pitman Press, Bath, Avon.

Contributors

PRINCIPAL AUTHORS AND SCIENTIFIC EDITOR-IN-CHIEF

- BIRGER BLOMBÄCK** *Professor, Department of Coagulation Research, Karolinska Institute, Stockholm, Sweden.*
- LARS Å. HANSON** *Professor, Senior Physician, Department of Clinical Immunology, Institute of Medical Microbiology, University of Gothenburg, Gothenburg, Sweden.*

ADDITIONAL CONTRIBUTORS

- LARS-OLOV ANDERSSON** *Associate Professor, Department of Biochemical Research, KABI AB, Sweden.*
- HANS BENNICH** *Associate Professor, Biomedicum, University of Uppsala, Uppsala, Sweden.*
- GUNNAR BIRKE** *Professor, Senior Physician, Medical Clinic, Huddinge Hospital, Huddinge, Sweden.*
- HENRIK BJÖRLING** *Research Engineer, Research Department, KABI AB, Sweden.*
- GITTEN CEDERBLAD** *Associate Professor, Department of Clinical Chemistry, University Hospital, Linköping, Sweden.*
- GÖRAN CLAES** *Associate Professor, Senior Physician, Surgical Clinic, Central Hospital, Borås, Sweden.*
- MONICA EINARSSON** *Ph.D., Department of Biochemical Research, KABI AB, Sweden.*
- BENGT GUILLBRING** *Senior Physician, Director of Stockholm Blood Center, Stockholm, Sweden.*
- ANDERS GUSTAFSON** *Professor, Senior Physician, Medical Clinic, University Hospital, Lund, Sweden.*
- LARS HOLMBERG** *Associate Professor, Senior Physician, Coagulation Laboratory and Paediatric Clinic, General Hospital, Malmö, Sweden.*
- BENGT G. JOHANSSON** *Associate Professor, Senior Physician, Department of Clinical Chemistry, University Hospital, Lund, Sweden.*
- STEN-OTTO LILJEDAHL** *Professor, Senior Physician, Surgical Clinic, University Hospital, Linköping, Sweden.*
- RAGNAR LUNDÉN** *Ph.D., Department of Biochemical Research, KABI AB, Sweden.*
- STAFFAN MAGNUSSON** *Associate Professor, Head of the Department of Molecular Biology, University of Aarhus, Århus, Denmark.*
- GÖRAN MÖLLER** *Associate Professor, Department of Immunobiology, Karolinska Institute, The Wallenberg Laboratory, Lilla Frescati, Stockholm, Sweden.*

vi Contributors

HUGO NIHLÉN
(Now deceased)

Master of Engineering, Department of Biochemical Research, KABI AB, Stockholm, Sweden.

KAI O PEDERSEN

Associate Professor, Institute of Physical Chemistry, University of Uppsala, Sweden.

JOHANNES A G RHODIN

Professor, Department of Anatomy, Karolinska Institute, Stockholm, Sweden.

MARK ROTHSCHILD

Professor, Radio Isotope Service and Nuclear Medicine, Veterans Administration Hospital, New York, USA.

PER WALLÉN

Associate Professor, Department of Medical Chemistry, Institute of Chemistry, University of Umeå, Umeå, Sweden.

FOREWORD

JAN G WALDENSTRÖM
COORDINATING EDITOR
HÅKAN WINBERG

Emeritus Professor, General Hospital, Malmö, Sweden.

Ph. D., KABI AB, Sweden.

Foreword

When I started in medical school some 50 years ago, we did not learn much about serum proteins. The textbook we used in physiological chemistry devoted only a few pages to this topic. We were taught that the serum contained albumin and globulins of two kinds: euglobulin and pseudoglobulin. Fibrinogen was of course regarded as an important substance but our knowledge regarding the mechanisms involved in coagulation of the blood was minimal. It is therefore fair to state that I have myself had a chance to follow practically the whole development leading to the present state of knowledge as it is described in this book. This history has been written in a superb way by Kai Pedersen in the first chapter.

I had the good fortune to enjoy collaboration with the group that was inspired by The Svedberg and Arne Tiselius. My first study with Kai Pedersen in 1937 was connected with a problem much discussed at that time. The German clinician Bennhold was a very original investigator with great imagination. He wrote some papers on the function of the plasma proteins and especially the albumin as vehicles for smaller molecules. When these were carried on the big protein molecules, they could stay in the circulation. This idea has of course been very fruitful. Bennhold attacked the problem from many aspects and his work has remained of fundamental importance. He also studied a very interesting experiment of nature, when he found two sibs, who had genetically determined almost complete lack of serum albumin but still got along fairly well. Pedersen and I were interested in the binding of bilirubin to albumin and we studied this problem in different clinical conditions with the aid of electrophoresis and ultracentrifugation.

I also had the pleasure to follow Tiselius and Pedersen when they developed new methods and discovered new facts. At this time we thought that the new names on the different serum protein fractions alpha, beta, and gamma were very special and sophisticated. They represented facts that chiefly had a theoretical, basic interest. A few years later Tiselius came back from New York and told us, laughing, that the gamma globulins had become very popular. The women in New York were parading the streets with placards inscribed: 'We want gamma globulins'. This was during a certain phase of the polio campaign.

At first glance the reader of this book will find many things that may seem very specialized. It is evident that the presentation—attempting to be complete—has to include many seemingly trivial and unimportant facts. At the same time it is quite clear that we cannot at present imagine which facts will be discussed by everybody in a few years' time. I think that it is very important to provide the kind of presentation of the facts that Kabi has given us. Earlier this company made an excellent contribution to the postgraduate education of the doctor when it edited and distributed a monograph on blood coagulation. The new volume on plasma proteins is another work with an identical aim and I think that it should be stressed that this book is not a textbook

meant to be read from cover to cover. The reader who is more technically minded will be provided with recent and correct facts regarding methodology. It is probable that this does not interest the clinician who may enjoy reading other chapters that attempt to integrate basic chemistry with clinical application. In this way I feel that the book will be widely read because the individual will find presentations of subjects that interest him in a special way.

It may well be said that this is natural with a Swedish book on plasma proteins. Swedish investigators, from the times of Olof Hammarsten to The Svedberg and Arne Tiselius and the teams working with these men, have contributed decisive knowledge regarding these substances. The development of new methods in this field has been initiated by Swedish work on such subjects as electrophoresis, ultracentrifugation, and gel filtration. Swedish industry has been very active in the technical development and Kabi has been in the front line regarding preparation of different fractions in such a pure condition that they may be used in clinical medicine. The previous Swedish edition was very well accepted and it seems appropriate to print this English edition that has been revised and brought up to date on several points.

There has been a lively discussion regarding the most ideal form of therapy imaginable. Perhaps a chemotherapeutic preparation or an antibiotic that stops the further growth of a deadly bug? A cytostatic that slows down the growth of a malignant cell or under favourable circumstances causes 'eradication of the last cell', an expression that has recently become popular among oncologists? Personally I have always been of the opinion that we have only one really ideal form of therapy. That is substitution. When a deficiency of a certain kind is corrected, either a complicated vitamin molecule or the simple iron atom, we combine natural healing and natural sciences. Substitution is always physiological and carries no risks. All over the world it has become a fashion among the mass media to repeat endless stories about the many real or invented dangers of drugs. Under such circumstances it is easy to forget the millions of patients, whose lives have been saved, when we are talking about a few exceptions. This volume treats the possibilities of giving natural substitution. Kabi has for several decades been active in strengthening our therapeutical armament with a number of important preparations. Therefore, this presentation of the facts from many of the collaborators in the programme is of special interest. The importance of gamma globulin preparations as a prophylactic can hardly be overrated but also other plasma protein fractions have gained increasing importance. We do not need much imagination in order to expect that purified proteins of the blood will become valuable in new fields.

My guess is that some readers will find the content of the chapters somewhat unbalanced. Such things are unavoidable in a book with many authors representing completely different training and interests. Nevertheless I am sure that the book is very valuable as a source of information both for doctors practising in the field and for biochemists. Plasma proteins will be a subject with increasing importance during years to come.

*General Hospital,
Malmö, Sweden*

JAN G. WALDENSTRÖM
Emeritus Professor

Preface

The fractionation of human blood plasma has long been one of Kabi's most important fields of interest. Today Kabi can offer a wide range of plasma protein products for therapeutic use, albumin, specific immunoglobulins, fibrinogen, specific blood coagulation factors, and several other isolated proteins for research purposes.

The development of research in clinical coagulation as a new, far-reaching and important discipline together with the ever increasing understanding of the mechanism of fibrinolysis was the background to Inga Marie Nilsson's widely used book, *Haemorrhagic and Thrombotic Diseases*, which appeared in English in 1974.

The present book, *Plasma Proteins*, is complementary to Inga Marie Nilsson's book. The scientific editors-in-chief are Birger Blombäck and Lars Å. Hanson.

We wish to express our warm thanks to the editors-in-chief and to the other contributors who through their efforts have made this book possible.

It is our hope that *Plasma Proteins* will be of use as an educational textbook and as a clinical handbook.

KABI AB
Stockholm

Contents

FOREWORD	xv
PREFACE	xvii
HISTORY	1
THE COMPOSITION OF HUMAN PLASMA	17
MICROCIRCULATION OF BLOOD.	23
INDUSTRIAL PLASMA FRACTIONATION METHODS	29
I. Cohn fractionation	29
II. The Kabi fractionation methods	30
1. AHF (Factor VIII).	31
2. Fibrinogen	33
3. Factor IX concentrate	34
4. Plasminogen and plasmin	34
5. Gamma globulin	34
6. Transferrin, haptoglobin, and ceruloplasmin.	36
7. Albumin	36
8. Glycoproteins	37
III. Other methods for industrial plasma fractionation	37
1. Ammonium sulphate precipitation methods.	37
2. Ether fractionation.	38
3. Rivanol precipitation	38
4. Precipitation with synthetic polymers	39
5. Chromatographic methods	39
TRANSPORT PROTEINS	
I. Serum albumin	43
A. Biochemistry	43
1. Purification and determination	43
2. Physiochemical properties	43

3. Heterogeneity	46
4. Chemical properties	47
5. Binding properties	51
6. Structure and function	53
B. Physiology and clinical aspects	54
1. Normal values	55
2. Synthesis, distribution, and breakdown.	56
3. Regulation of albumin metabolism	56
4. Synthesis of albumin	56
5. Factors affecting the synthesis of albumin.	58
6. Distribution of albumin	60
7. Breakdown of albumin	61
8. Albumin in illness—clinical and therapeutical points of view.	63
9. Special conditions of hypo- albuminaemia	67
10. Treatment with albumin.	69
C. Organ storage by continuous albumin perfusion	71
II. Plasma lipoproteins.	72
A. Introduction and terminology.	72
1. Plasma lipids—the lipid components in plasma lipoproteins	73
B. Lipid metabolism	74
C. Lipoproteins in plasma	76
1. Chylomicrons	76
2. VLDL (pre- β -lipoproteins)	76
3. LDL (β -lipoproteins)	77
4. HDL (α -lipoproteins)	77
D. Abnormal lipoproteins	78
1. Lipoprotein X (LP-X).	78
2. Sinking pre- β -LP (SPB) Lp (a+).	78
3. Floating β -lipoproteins	79
E. Lipoprotein families, apolipoproteins, and their polypeptides.	79
F. Methods used in the study of plasma lipoproteins	82
1. Electrophoresis	82
2. Preparative ultracentrifugation	82
3. Methods of precipitation	82
4. Nephelometry	83
5. Immunochemical methods	83
6. Quantification of LP	83
G. Methods used in the study of LP families	83

H. Methods used in the study of apolipoproteins and their peptides	84
I. Structure of plasma lipoproteins	84
J. Lipoprotein metabolism	84
1. Synthesis	84
2. Catabolism of chylomicrons	86
3. Catabolism of VLDL	87
4. Catabolism of LDL	87
5. Catabolism of HDL	88
K. Factors influencing concentration of LP in plasma	88
L. Hyperlipidaemia and hyperlipo- proteinaemia	90
M. Hyperlipoproteinaemias and their clinical manifestations	91
N. Reference values and frequency of hyperlipoproteinaemia.	93
O. Hypolipoproteinaemias	93
1. Tangier's disease	93
2. LP-A deficiency.	93
3. Lecithin-cholesterol-acyl-transferase (LCAT) deficiency	93
4. A- β -lipoproteinaemia (Bassen-Kornzweig disease).	94
III. Plasma proteins involved in haem metabolism and in transport of metals, hormones, and vitamins	94
A. Ceruloplasmin	96
1. Chemical structure and biochemistry	96
2. Biological function.	97
3. Hereditary defects in copper metabolism	99
B. Transferrin	99
1. Chemical structure and biochemistry	99
2. Genetic variants	100
3. Biological function.	100
C. Haptoglobin	102
1. Chemical structure and biochemistry	102
2. Genetic variants	105
3. Biological function.	106
D. Haemopexin	106
1. Chemical structure and biochemistry	106
2. Biological function.	107
E. Transcobalamine	109
1. Chemical structure and biochemistry	109
2. Biological function.	110
3. Genetic variants	110
F. Retinol-binding protein	111
1. Chemical structure and biochemistry	111
2. Biological function.	112

G. Proteins binding thyroid hormones	113
1. Chemical structure and biochemistry	113
2. Genetic variants	114
3. Biological function.	114
H. Transcortin	115
1. Chemical structure and biochemistry	115
2. Biological function.	116

IMMUNOGLOBULINS

I. Structure and biochemistry	119
1. Basic structure	119
2. Classes of immunoglobulins	120
3. Structures of heavy chains of various classes	121
4. Variable and constant regions.	124
5. Antigenic properties of immunoglobulins: isotypes, allotypes, and idiotypes	125
6. Biosynthesis of immunoglobulins.	126
II. Immunological mechanisms	127
1. The lymphatic system	128
2. Characteristics of antigens.	131
3. Antibody formation	132
4. Cell-mediated immunity	137
5. Antigen-antibody reactions	140
6. Complement	147
III. Defence against infection	151
1. Non-specific defence mechanisms	152
2. Role of antibodies	156
3. Cell-mediated immunity	163
4. Defects in the defence mechanisms.	164
IV. Immunological diseases: allergies, immune complex diseases, and autoimmune disease	174
1. Mechanisms of immunological diseases	174
2. Atopic allergies	176
3. Drug allergies	181
4. Contact allergies	182
5. Immune complex diseases.	182
6. Autoimmune diseases	184
V. Transplantation immunology	187
1. Histocompatibility antigens	187
2. Immune reactions against transplanted tissue	188
3. The effector function	189
4. Clinical aspects	190
5. Immunosuppression	193

VI. Tumour immunology	194
1. Tumour antigens	194
2. Immune reactions	195
3. Immunological surveillance	195
4. Practical applications of tumour immunology	197
VII. Blood group serology	198
A. Introduction	198
1. Definitions	198
2. Cell membrane	198
3. Erythrocyte antigens.	199
4. Blood group antibodies	200
5. Antiglobulin sera for the demonstration of antibodies (Coombs's test)	202
6. Frequency of blood group antibodies.	203
B. Genetics of blood groups	204
C. ABO and Lewis systems.	205
1. ABO system	205
2. Antibodies within the ABO system	206
3. Reactions towards transfusion which are caused by incompatible ABO blood	207
4. ABO incompatibility as a cause of haemolytic diseases in the new-born	207
5. The Lewis system.	208
6. ABH and Lewis antigens in secretion.	208
7. Chemical composition of blood group substances	210
D. Rh system	210
1. Nomenclature	211
2. Frequencies of Rh types	212
3. Rh antibodies	213
4. The D antigen.	213
5. Special antigens within the Rh system	214
6. Rh immunization.	215
7. Rh prophylaxis	217
E. Certain blood group systems of clinical interest	218
1. The Kell system	218
2. The Duffy system.	219
3. The Kidd system	219

PROTEINS TAKING PART IN COAGULATION AND FIBRINOLYSIS

I. Factors and mechanisms involved in blood coagulation	221
---	-----

II. Fibrinogen and fibrin formation	223
1. Occurrence and role.	223
2. Physicochemical properties	224
3. The subunits and prosthetic groups of fibrinogen	227
4. The primary structure of fibrinogen	230
5. Fibrin—the ordered structure of fibrinogen	237
6. Stabilizing the fibrin polymer	247
7. The antigenic structure of fibrinogen and the location of epitopes and other structural elements	249
8. Fibrinogen in health and disease	250
9. Epilogue	253
III. Thrombin and prothrombin	254
A. Limited proteolysis as a means of regulation	254
B. Historical outline	254
C. Thrombin—structure and function	255
1. Function and specificity	255
2. Primary structure.	256
3. Homology with serine proteases and haptoglobin	258
4. Tentative tertiary structure	259
5. Partial homology/analogy with angiotensin and with luteinizing hormone (LH)	260
D. Prothrombin—structure and activation	261
1. Specific cleavage by factor X_a and by thrombin. Nomenclature	261
2. The primary structure of prothrombin. Internal homology. ‘Kringel’ structures	262
3. γ -Carboxylglutamic acid, Ca^{2+} and phospholipid binding, vitamin K	264
4. Homology with plasminogen.	268
5. Homology with other vitamin-K-dependent proteins	268
6. Partial homology with the pancreatic secretory trypsin inhibitor (Kazal’s inhibitor) and with hirudin	273
7. Activation by limited proteolysis	274
8. Activation by staphylocoagulase	275
9. Multiple evolutionary origin of the larger serine protease zymogen structures	275
E. Biosynthesis	275
F. Inhibition of thrombin by antithrombin-III (heparin cofactor)	276
IV. AHF and von Willebrand’s disease	276
V. Haemophilia B-factor (Factor 1X).	281
VI. Additional coagulation factors	285
1. Factor V.	285
2. Factor VII	286
3. Factor X.	286
4. Factor XI	287
5. Factor XII	287

6. Factor XIII	287
VII. Plasminogen and fibrinolysis	288
1. Introduction	288
2. Plasminogen: purification and properties	289
3. Activation of the fibrinolytic system	293
4. Activators	299
5. Inhibition of fibrinolysis	303
6. Interactions between fibrin and the fibrinolytic system	304

INHIBITORS OF PROTEOLYSIS IN PLASMA

1. α_1 -Antitrypsin	305
2. α_2 -Protease inhibitor, antiplasmin	306
3. α_2 -Macroglobulin	307
4. Antithrombin	307

PLASMA PROTEINS AS DIAGNOSTIC AIDS. METHODS AND CLINICAL APPLICATIONS

I. Introduction	309
II. Chemical methods	309
1. Determination of total protein	309
2. Determination of individual plasma proteins	311
III. Physicochemical methods.	312
1. Analytical ultracentrifugation	312
2. Gel filtration	313
3. Electrophoresis	316
IV. Immunochemical methods	318
1. Introduction	318
2. Quantitative precipitation in solution.	321
3. Double diffusion in agar gel	323
4. Immuno-electrophoresis.	323
5. Quantitative gel immunodiffusion	324
6. Electroimmunoassay (rocket immuno-electrophoresis)	325
7. Crossed immuno-electrophoresis.	329
8. Other gel immunoprecipitation techniques	330
9. Nephelometric determinations of immunoprecipitates	333
10. Radioimmunoassay	333
V. Diagnostic use of plasma protein analysis	335
1. The normal agarose electrophoresis pattern	335
2. Normal variants of the electrophoretic plasma protein pattern	337
3. Pathological variations in the electrophoretic patterns	338
4. Normal variations in the concentrations of individual plasma proteins.	339

5. Influence of steroid hormones on the plasma protein pattern.	341
VI. Deficiency states – α_1 -antitrypsin deficiency	343
VII. Immunoglobulin alterations in disease	344
1. Decrease in the level of immunoglobulin	344
2. Monoclonal increase of immunoglobulins	345
3. Oligoclonal and polyclonal immunoglobulin increase	348
VIII. The plasma protein profile in inflammatory conditions	351
IX. Plasma protein changes in gastrointestinal diseases	354
X. Plasma protein alterations in liver and biliary diseases	357
1. Hepatitis and liver cirrhosis	357
2. Liver tumours	360
3. Protein and lipoprotein changes in cholestasis	360
XI. Kidney disease	361
XII. Blood and bone marrow diseases	362
XIII. Analysis of proteins in body fluids other than blood	364
1. Urinary proteins	364
2. Cerebrospinal fluid proteins	368
REFERENCES	377
INDEX	393

History

KAI O. PEDERSEN

Proteins are essential in animal nutrition and they are therefore of fundamental importance for all living beings. This was the reason why Berzelius in 1838, in a correspondence with the Dutch chemist G. J. Mulder, proposed the introduction of the name protein. Mulder had studied a number of nitrogenous substances prepared from animal and plant material and had come to the conclusion that all these substances had one part in common. The difference in the material of different origin was explained by variation in the content of bound sulphur and phosphorus. The name protein was derived from a Greek word meaning 'of first rank' and should thus stress the primary importance of these substances.

Blood plasma is a solution consisting of a mixture of virtually hundreds of individual proteins, some of them in very small amounts. It is therefore not surprising that more than a century passed after the separation of the first proteins before enough information was obtained to allow the understanding of the finer molecular structure of this fascinating group of substances.

Now we know that proteins are macromolecules and are among the most complicated of organic molecules. They are built up from hundreds of α -amino acids linked together through so-called peptide bonds into one or several long chains (primary structure). Linus Pauling and co-workers have shown that the peptide chain is often folded in a spiral, the so-called α -helix. This spiral is stabilized by various bindings between amino acids which, due to the folding, have come relatively close together in space (secondary structure). The α -helix is folded further into a more compact tertiary structure kept together by, for instance, disulphide linkages between amino acids in different parts of the α -helix. These units may further be bound together to still larger units by interchain bridges.

The secondary and tertiary structures are of fundamental importance for the properties of the native proteins. If this delicate structure is changed, for instance by heating to 50–70°C or by adding some organic solvents to the protein solution, the properties of the protein may be profoundly changed—the protein becomes denatured.

In the middle of the nineteenth century it was found that a fraction of the plasma and serum proteins could be precipitated by dilution with slightly acidified water or by the addition of, for example, sodium chloride to saturation. This protein was given various names until finally it was called globulin. The protein remaining in solution was called albumin. At this time it was discovered by T. Graham that proteins would not pass through membranes permeable to ordinary salts. Protein solutions could therefore be freed from salts by dialysis. When dissolved, the proteins formed colloidal solutions having very large particles.

In the later half of the nineteenth century, many different separation methods were introduced into protein chemistry. It was found that a number of neutral salts would precipitate proteins reversibly without denaturation. Thus in 1879 Olof Hammarsten at